Drugs Losing Exclusivity in 2027 & Key Intermediates
3 drugs expire in 2027 (public sources), 3 with recorded synthesis routes; key intermediates of 3 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| Palbociclib | A · Act now | 2027 | Breast cancer | 5 | 52 | Available ×52 |
| Ibrutinib | A · Act now | 2027 | Waldenström macroglobulinaemia, Chronic lymphocytic leukaemia, Mantle cell lymphoma | 33 | 150 | Available ×18 |
| Enzalutamide | A · Act now | 2027 | Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Prostate cancer | 4 | 15 | Available ×1 |
Frequently asked questions
Which drugs lose exclusivity in 2027?
3 drugs expire in 2027 per public sources: Ibrutinib, Palbociclib, Enzalutamide.
When should we start sourcing intermediates for 2027 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 3 of the 3 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-29